Combination therapy with nivolumab and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.

被引：0
|
作者：
Garmezy, Benjamin
Zhang, Tian
Laccetti, Andrew Leonard
Economides, Minas P.
Shah, Amishi Yogesh
Tannir, Nizar M.
Jonasch, Eric
Msaouel, Pavlos
Zurita, Amado J.
Corn, Paul Gettys
Venkatesan, Aradhana M.
Brown, Landon Carter
Kao, Chester
Kinsey, Emily Noelle
Harrison, Michael Roger
Armstrong, Andrew J.
George, Daniel J.
Campbell, Matthew T.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Duke Canc Inst, Durham, NC USA
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17090
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Long term toxicity of tyrosine kinase inhibitors (TKIs) in patients with metastatic clear cell renal cell carcinoma (RCC)
    Vakkalanka, B. K.
    Elson, P.
    Wood, L.
    Dreicer, R.
    Garcia, J. A.
    Bukowski, R. M.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors
    Roviello, Giandomenico
    Catalano, Martina
    De Giorgi, Ugo
    Maruzzo, Marco
    Buti, Sebastiano
    Gambale, Elisabetta
    Procopio, Giuseppe
    Ottanelli, Carlotta
    Caliman, Enrico
    Isella, Luca
    Sepe, Pierangela
    Brighi, Nicole
    Santoni, Matteo
    Galli, Luca
    Conca, Raffaele
    Doni, Laura
    Antonuzzo, Lorenzo
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [43] Immunoscore System for Predicting Clinical Outcome of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors
    Yao, Jia-Xi
    Chen, Xiang
    Xi, Wei
    Zhu, Yan-Jun
    Wang, Hang
    Hu, Xiao-Yi
    Guo, Jian-Ming
    JOURNAL OF CANCER, 2018, 9 (22): : 4099 - 4107
  • [44] Prosnostic Significance of Prognostic Nutrition Index in Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors
    Tacar, Seher Yildiz
    Yilmaz, Mesut
    Gulturk, Ilkay
    Tural, Deniz
    NAMIK KEMAL MEDICAL JOURNAL, 2022, 10 (03): : 228 - 234
  • [45] Systemic Inflammatory Biomarkers Predict Survival of Patients Treated With Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
    Wang, Zhaojuan
    Qin, Yujie
    Chai, Xuxia
    Lu, Lina
    Xue, Ping
    Lu, Runrun
    Miao, Chengrui
    Ma, Haimei
    Hu, Xiaoyi
    Yao, Jiaxi
    CANCER CONTROL, 2023, 30
  • [46] Thyroid Dysfunction in Patients Treated with Tyrosine Kinase Inhibitors, Sunitinib, Sorafenib and Axitinib, for Metastatic Renal Cell Carcinoma
    Daimon, Makoto
    Kato, Tomoyuki
    Kaino, Wataru
    Takase, Kaoru
    Karasawa, Shigeru
    Wada, Kiriko
    Kameda, Wataru
    Susa, Shinji
    Oizumi, Toshihide
    Tomita, Yoshihiko
    Kato, Takeo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (08) : 742 - 747
  • [47] Sequential Tyrosine Kinase Inhibitors (TKIs) in Metastatic Renal Cell Carcinoma: Results from a Large Cohort of Patients
    Biondani, Pamela
    Verzoni, Elena
    Torri, Valter
    Porcu, Luca
    Grassi, Paolo
    Testa, Isabella
    De Braud, Filippo
    Procopio, Giuseppe
    ANTICANCER RESEARCH, 2014, 34 (05) : 2395 - 2398
  • [48] Combination therapy in metastatic renal cell carcinoma
    Heng, Daniel Y. C.
    LANCET ONCOLOGY, 2011, 12 (07): : 613 - 614
  • [49] Combination therapy for metastatic renal cell carcinoma
    Buonerba, Carlo
    Di Lorenzo, Giuseppe
    Sonpavde, Guru
    ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (05)
  • [50] Sequential use of mammalian target of rapamycin inhibitors in patients with metastatic renal cell carcinoma following failure of tyrosine kinase inhibitors
    Masafumi Kumano
    Hideaki Miyake
    Ken-ichi Harada
    Masato Fujisawa
    Medical Oncology, 2013, 30
12345